Mechanisms of resistance to antibody-drug conjugates in cancer therapy: molecular basis and therapeutic strategies
{{output}}
Antibody-drug conjugates (ADCs) have emerged as a transformative class in oncology, integrating the target specificity of monoclonal antibodies with the potent cytotoxicity of small-molecule payloads. By harnessing tumor-specific antigen recognition, ADCs enab... ...
